3 years ago

A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis

A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis
Adam Sateriale, Ravinder R. Kondreddi, Peter Gedeck, Christian G. Noble, Carrie F. Brooks, Sumiti Vinayak, Francesca Blasco, Laura B. Goodman, Siau H. Lim, Suresh B. Lakshminarayana, Lijun Zhang, Tracy Sy, Thierry T. Diagana, Boris Striepen, Bin Zou, Ghislain M. C. Bonamy, Jayesh Tandel, F. Joel Leong, Gu Feng, Susan Noh, Ujjini H. Manjunatha, Christophe Bodenreider, Alexander T. Chao, Juergen Wagner, Gillian T. Herbert, Jennifer A. Zambriski
Diarrhoeal disease is responsible for 8.6% of global child mortality. Recent epidemiological studies found the protozoan parasite Cryptosporidium to be a leading cause of paediatric diarrhoea, with particularly grave impact on infants and immunocompromised individuals. There is neither a vaccine nor an effective treatment. Here we establish a drug discovery process built on scalable phenotypic assays and mouse models that take advantage of transgenic parasites. Screening a library of compounds with anti-parasitic activity, we identify pyrazolopyridines as inhibitors of Cryptosporidium parvum and Cryptosporidium hominis. Oral treatment with the pyrazolopyridine KDU731 results in a potent reduction in intestinal infection of immunocompromised mice. Treatment also leads to rapid resolution of diarrhoea and dehydration in neonatal calves, a clinical model of cryptosporidiosis that closely resembles human infection. Our results suggest that the Cryptosporidium lipid kinase PI(4)K (phosphatidylinositol-4-OH kinase) is a target for pyrazolopyridines and that KDU731 warrants further preclinical evaluation as a drug candidate for the treatment of cryptosporidiosis.

Publisher URL: http://dx.doi.org/10.1038/nature22337

DOI: 10.1038/nature22337

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.